.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Chinese Patent Office
Federal Trade Commission
Covington
Cantor Fitzgerald
Mallinckrodt
Express Scripts
Fuji
Boehringer Ingelheim
Cipla

Generated: November 19, 2017

DrugPatentWatch Database Preview

Apotex Technologies Company Profile

« Back to Dashboard

What is the competitive landscape for APOTEX TECHNOLOGIES, and what generic alternatives to APOTEX TECHNOLOGIES drugs are available?

APOTEX TECHNOLOGIES has four approved drugs.

There are five US patents protecting APOTEX TECHNOLOGIES drugs.

There are two hundred and thirteen patent family members on APOTEX TECHNOLOGIES drugs in fifty-one countries.

Summary for Apotex Technologies

International Patents:213
US Patents:5
Tradenames:2
Ingredients:1
NDAs:4
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Technologies
PAXIL
paroxetine hydrochloride
CAPSULE;ORAL020885-002Oct 9, 1998DISCNYesNo► Subscribe► SubscribeY► Subscribe
Apotex Technologies
PAXIL CR
paroxetine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020936-002Feb 16, 1999ABRXYesNo► Subscribe► SubscribeY► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
TABLET;ORAL020031-003Dec 29, 1992ABRXYesNo► Subscribe► SubscribeY► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
CAPSULE;ORAL020885-001Oct 9, 1998DISCNYesNo► Subscribe► SubscribeY► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
CAPSULE;ORAL020885-003Oct 9, 1998DISCNYesNo► Subscribe► SubscribeY► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
CAPSULE;ORAL020885-002Oct 9, 1998DISCNYesNo► Subscribe► SubscribeY► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
CAPSULE;ORAL020885-004Oct 9, 1998DISCNYesNo► Subscribe► SubscribeY► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
CAPSULE;ORAL020885-001Oct 9, 1998DISCNYesNo► Subscribe► SubscribeY► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
TABLET;ORAL020031-001Dec 29, 1992ABRXYesNo► Subscribe► SubscribeY► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
TABLET;ORAL020031-004Dec 29, 1992DISCNNoNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Apotex Technologies

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apotex Technologies
PAXIL
paroxetine hydrochloride
SUSPENSION;ORAL020710-001Jun 25, 1997► Subscribe► Subscribe
Apotex Technologies
PAXIL CR
paroxetine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020936-001Feb 16, 1999► Subscribe► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
TABLET;ORAL020031-003Dec 29, 1992► Subscribe► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
CAPSULE;ORAL020885-001Oct 9, 1998► Subscribe► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
TABLET;ORAL020031-002Dec 29, 1992► Subscribe► Subscribe
Apotex Technologies
PAXIL CR
paroxetine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020936-002Feb 16, 1999► Subscribe► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
CAPSULE;ORAL020885-004Oct 9, 1998► Subscribe► Subscribe
Apotex Technologies
PAXIL CR
paroxetine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020936-003Dec 6, 2000► Subscribe► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
CAPSULE;ORAL020885-003Oct 9, 1998► Subscribe► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
TABLET;ORAL020031-003Dec 29, 1992► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for APOTEX TECHNOLOGIES drugs

Drugname Dosage Strength Tradename Submissiondate
paroxetine hydrochloride
Extended-release Tablets37.5 mg
PAXIL CR
5/19/2009
paroxetine hydrochloride
Extended-release Tablets25 mg
PAXIL CR
9/9/2005
paroxetine hydrochloride
Oral Suspension10 mg/5 mL
PAXIL
2/10/2005

International Patent Family for Apotex Technologies Drugs

Country Document Number Estimated Expiration
Japan2006265258► Subscribe
Germany69630603► Subscribe
European Patent Office1064936► Subscribe
Greece990100140► Subscribe
Greece3034328► Subscribe
Turkey9800077► Subscribe
Mexico9800571► Subscribe
China1314906► Subscribe
Peru16098► Subscribe
IrelandS990343► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Fuji
Baxter
Cerilliant
UBS
Julphar
US Army
Argus Health
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot